



**Meeting of the Strategic Advisory Group of Experts (SAGE) on Immunization  
31 March – 01 April 2020  
Virtual Meeting  
Draft agenda**

**Tuesday 31 March 2020**

| <b>Time</b>  | <b>Session</b>   | <b>Purpose of session, target outcomes and questions for SAGE</b>   | <b>Duration</b> |
|--------------|--|---|-----------------|
| 10:00        | <b>Closed SAGE meeting</b>   | Preparation of the sessions of the day. Other important discussion items.   | 1h              |
| 11:00        | <b>Welcome – introduction of participants</b><br><br>A. CRAVIOTO. Chair of SAGE.   |   | 10 min.         |
| 11:10        | <b>Report from Director, IVB - Session 1</b><br><br>Global report. K. O'BRIEN. WHO. 20 min.<br><br>Updates from the Regions. 20 min.<br><br>Discussion: 50 min.  | <b>FOR INFORMATION</b>  | 1h 30 min.      |
| <b>12:40</b> | <b>Break</b>   | <b>Break</b>  | <b>15 min.</b>  |
| 12:55        | <b>Measles outbreak epidemiology and WHO coordination - Session 2</b><br><br>Measles rubella update (with focus on current outbreaks). 10 min.<br><br>WHO's and global response to measles outbreaks. 15 min.<br><br>Measles-rubella policies and strategies to present current policy landscape and advise SAGE of upcoming measles rubella strategic work and policy needs. 10 min.<br><br>Discussion: 25 min. | <b>FOR DISCUSSION</b>   | 1h              |
| <b>13:55</b> | <b>Break</b>   | <b>Break</b>  | <b>30 min.</b>  |
| 14:25        | <b>Update on SARS-CoV2 vaccine development- Session 3</b>  |   | 1h              |
| <b>15:25</b> | <b>Break</b>   | <b>Break</b>  | <b>15 min.</b>  |
| 15:40        | <b>Update on Ebola - Session 4</b>   | <b>FOR INFORMATION</b><br><br>Update on the Ebola epidemic in DRC, on vaccine use and safety reports, and other vaccine developments. | 30 min.         |
| <b>16:10</b> | <b>End of Day</b>  |   |                 |

**Wednesday 01 April 2020**

|              |   |  |                |
|--------------|---|--|----------------|
| 10:00        | <b>Closed SAGE meeting</b>  | Preparation of the sessions of the day. Recap of day 1. Other important discussion items.  | 1h             |
| 11:00        | <b>Polio - Session 5</b>  | <b>FOR DISCUSSION AND DECISION</b>   | 2h 30 min.     |
|              | Update from the Global Polio Eradication Initiative. M. ZAFFRAN. WHO. 15 min.   | SAGE will be informed on the current status of the polio eradication program; revised strategies to respond to cVDPV outbreaks; and nOPV2 development.   |                |
|              | Questions: 5min.  |  |                |
|              | Update on cVDPV2 epidemiology and overview of the new cVDPV2 outbreak response strategy focusing on tOPV and IPV use. O. MACH. WHO. 15 min.   | SAGE will be asked to review and consider for endorsement:   |                |
|              | Questions: 5 min.   |  |                |
|              | Update on nOPV2 development:  |  |                |
|              | <ul style="list-style-type: none"> <li>Summary of nOPV2 clinical data. A. BANDYOPADHYAY. BMGF. 15 min.</li> <li>Framework for initial-use of nOPV2 under Emergency Use Listing (EUL). G. MACKLIN. WHO. 15 min.</li> </ul> | <ul style="list-style-type: none"> <li>Policy implications of the new cVDPV2 outbreak response strategy (tOPV and IPV use)</li> <li>Framework for initial use of nOPV2.</li> </ul>   |                |
|              | Discussion: 30 min.   |  |                |
|              | Report from SAGE Polio Working Group including recommendations for regions considering switch to IPV only schedules. I. JANI. SAGE Member. 20 min.  |  |                |
|              | Discussion: 30 min.   |  |                |
| <b>13:30</b> | <b>Break</b>  | <b>Break</b>   | <b>30 min.</b> |
| 14:00        | <b>IA2030 Monitoring and Evaluation framework - Session 6</b>   | <b>FOR DISCUSSION</b>  | 1h             |
|              | Update SAGE about the status of M&E Framework development, processes and content. 30 min.   | 1. Share updates from the IA2030 M&E Task Force, including:  |                |
|              | Discussion: 30 min.   | <ul style="list-style-type: none"> <li>Aims and principles of IA2030 Monitoring, Evaluation &amp; Action (ME&amp;A) Framework</li> <li>IA2030 ME&amp;A Framework development process</li> <li>Revised IA2030 Strategic Priority (SP) Goals and Objectives</li> <li>Possible links of IA2030 ME&amp;A Framework to Governance &amp; Accountability mechanisms</li> <li>How GVAP lessons learned inform development of the IA 2030 ME&amp;A Framework</li> </ul> |                |
|              |   | 2. Receive feedback from SAGE on:  |                |
|              |   | <ul style="list-style-type: none"> <li>IA2030 ME&amp;A Framework development process</li> <li>Options for development of IA2030 ME&amp;A Framework indicators and targets</li> <li>Possible links of IA2030 ME&amp;A Framework to Governance &amp; Accountability mechanisms</li> </ul>  |                |
| <b>15:00</b> | <b>Break</b>  | <b>Break</b>   | <b>15 min.</b> |
| 15:15        | <b>Global Vaccine Safety Blueprint 2.0 - Session 7</b>  | <b>FOR DISCUSSION AND DECISION</b>   | 1h             |
|              | Introduction. K. JOHANSEN. SAGE member. 5 min.  | For revision and endorsement of the Global Vaccine Safety Blueprint 2.0  |                |
|              | Global Vaccine Safety Blueprint 2.0. E. Asturias-D. Salmon. (TBC). 15 min.  | Questions to SAGE proposed by GACVS:   |                |
|              | Discussion: 40 min.   |  |                |

09 March 2020

1. What strategic shift could be made to move from GVS1.0 to GVS2.0?
2. Are there strategies for identifying resources and mechanisms for finding funds without using those reserved for vaccination?
3. What are the recommendations for moving forward, including possible adjustments to the Global Vaccine Safety Initiative?

**16:15 End of the day**